<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04595799</url>
  </required_header>
  <id_info>
    <org_study_id>20-AOI-01</org_study_id>
    <nct_id>NCT04595799</nct_id>
  </id_info>
  <brief_title>Use of a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis.</brief_title>
  <acronym>MSST</acronym>
  <official_title>MS Screen Test: Using a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system for&#xD;
      which the investigators now have many treatment alternatives. These treatments have a&#xD;
      preventive goal and the data in the literature suggest the interest in rapidly achieving&#xD;
      optimal control of the disease in order to decrease the risk of long-term disability&#xD;
      progression.&#xD;
&#xD;
      One of the current unmet needs is to have markers that can be used at the individual level to&#xD;
      predict the long-term prognosis in order to propose optimal and personalized therapeutic&#xD;
      management.&#xD;
&#xD;
      Classically used clinical markers do not meet this need. It is recognized that there is a&#xD;
      so-called silent course of MS (not measurable by clinical parameters), which may, after&#xD;
      several months or years, be expressed as a physical or cognitive disability.&#xD;
&#xD;
      MRI is the reference examination for monitoring the sub-clinical activity of the disease but&#xD;
      it does not allow the neurodegenerative side of the disease to be assessed. Other blood or&#xD;
      imaging markers are being studied but are not yet usable in daily practice.&#xD;
&#xD;
      The project aims to evaluate the interest in using digital biomarkers, based on a rapid&#xD;
      assessment of patients using a locally developed mobile application (MS Screen Test - MSST)&#xD;
      to predict the evolutionary prognosis of the disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">November 9, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 9, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>speed test in MMST results</measure>
    <time_frame>12 months</time_frame>
    <description>the average speed (in taps per second or Hz) for the dominant and non-dominant hand</description>
  </primary_outcome>
  <primary_outcome>
    <measure>agility test in MMST results</measure>
    <time_frame>12 months</time_frame>
    <description>time required (in seconds) to bring the ball to the target as well as the actual time the ball will be held inside the target (expressed as a percentage of the total recording time)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>synchronization test in MMST results</measure>
    <time_frame>12 months</time_frame>
    <description>the average time interval expressed in milliseconds separating the left and right index strokes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>visual test in MMST results</measure>
    <time_frame>12 months</time_frame>
    <description>number of letters seen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive test in MMST results</measure>
    <time_frame>12 months</time_frame>
    <description>the average response latency (the time in milliseconds between the display and the click on a good answer) expressed in milliseconds, the number of wrong answers as well as the number of missed letters.&#xD;
the average response latency is the combination of multiple measurements (time of response, number of wrong answers and number of missed letters.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with newly diagnosed multiple sclerosis starting first-line background therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient between 18 and 60 years of age&#xD;
&#xD;
          -  Presenting a diagnosis of relapsing-remitting MS defined according to McDonald 2017&#xD;
             criteria confirmed within 6 months prior to inclusion&#xD;
&#xD;
          -  Starting first-line treatment (interferon beta, glatiramer acetate, teriflunomide,&#xD;
             dimethyl fumarate)&#xD;
&#xD;
          -  Having an encephalic and cervical MRI in OFSEP format, within 6 months prior to&#xD;
             inclusion&#xD;
&#xD;
          -  No relapse within 30 days prior to inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of a motor, visual or cognitive deficit not related to MS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MIKAEL COHEN</last_name>
    <phone>334 92 03 82 52</phone>
    <email>cohen.m@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene ZEPHIR</last_name>
      <email>Thi-helene.ZEPHIR@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Helene ZEPHIR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LYON Civil Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sandra VUKUSIC</last_name>
      <email>sandra.vukusic@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>sandra VUKUSIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montpellier university hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>pierre LABAUGE</last_name>
      <email>p-labauge@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>pierre LABAUGE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nice University Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIKAEL COHEN</last_name>
      <phone>334 92 03 82 52</phone>
      <email>cohen.m@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>MIKAEL COHEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nimes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>eric THOUVENOT</last_name>
      <email>eric.thouvenot@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>eric thouvenot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris University Hospital - la pitié salpétriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth MAILLART</last_name>
      <email>elisabeth.maillart@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>elisabeth MAILLART</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure Michel</last_name>
      <email>laure.michel@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Laure Michel</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Lepage</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rouen University hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand BOURRE</last_name>
      <email>Bertrand.Bourre@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>bertrand BOURRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strasbourg University Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome De SEZE</last_name>
      <email>Jerome.DESEZE@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>jerome de seze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toulouse university hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan CIRON</last_name>
      <email>ciron.j@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jonathan CIRON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

